Orano Med

🎗️ Today is World Cancer Day 🎗️ Each year, over 20 million people worldwide are diagnosed with cancer, making it one of the greatest public health challenges. Despite scientific progress, many needs remain unmet. #WorldCancerDay is a reminder that every step forward is crucial in the fight against cancer and in improving patients' lives. As a leader in targeted alpha therapy, Orano Med is working to address this challenge in two key ways: 🔬 By developing a diversified pipeline of innovative therapies using lead-212. 🌍 By ensuring a reliable supply of these innovative treatments through a fully integrated supply chain. At Orano Med, fighting cancer means not only developing new therapeutic solutions but also ensuring their accessibility to those who need them. This is our commitment. 💡🎯 Find out more on our website: https://lnkd.in/eBCaB-gm #WorldCancerDay #OranoMed #Orano #Pb212 #Radiopharmaceuticals #Innovation #CancerResearch #Cancer #Healthcare Orano

🎉 10,000 followers 🎉 We are thrilled to share that we have reached 10,000 followers on LinkedIn! Your support in our mission to fight cancer inspire us every day to go even further. 🌟 At Orano Med every success is made possible through teamwork. Together, we are dedicated to developing cutting-edge solutions and bringing real hope to cancer patients with unmet needs. 👉 Want to join us? Visit our website to explore all our open positions: https://lnkd.in/esmuDUJr --- 🎉 10 000 abonnés 🎉 Nous sommes ravis de partager que nous avons atteint les 10 000 abonnés sur LinkedIn ! Votre soutien à notre mission dans la lutte contre le cancer nous motive chaque jour à aller encore plus loin. 🌟 Chez Orano Med, chaque succès est rendu possible grâce au travail d'équipe. Ensemble, nous nous engageons à développer des solutions innovantes et à apporter de l'espoir aux patients en impasse thérapeutique. 👉 Vous souhaitez nous rejoindre ? Rendez-vous sur notre site pour découvrir toutes nos offres d’emploi : https://lnkd.in/deKZHjqh #OranoMed #Orano #LinkedIn #Pb212 #RLT #Radiopharmaceuticals #Innovation #CancerResearch #Cancer #Healthcare #PharmaJob Orano

A Look Back at #JPM2025 🔙   Last week, our team had the opportunity to meet with key players in the pharmaceutical and medical industries, discuss scientific advancements, and share our progress in the development of lead-212 based radioligand therapies at the 43rd Annual J.P. Morgan Healthcare Conference.   During these few days, we have reinforced our commitment to delivering new solutions for patients with unmet medical needs, confident in the potential of lead-212 based radioligand therapies and our strategy to advance cancer treatment.   💡 At Orano Med, we are focused on developing a diversified pipeline of radioligand therapies while ensuring a reliable supply of these innovative treatments through a fully integrated supply chain.   👏 We are grateful for the ongoing support of our partners Sanofi, Molecular Partners, and Roche. These partnerships are key to achieving our shared goal: making these therapies accessible to patients as soon as possible.   Arnaud Lesegretain Julien Torgue Thomas Daniel-Robin   #JPM2025 #OranoMed #Pb212 #RLT #Radiopharmaceuticals #Innovation #CancerResearch #Cancer #Healthcare

Big news to kick off 2025! 🚀 🌍 Orano Med at the 43rd Annual J.P. Morgan Healthcare Conference We are thrilled to be part of the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco! This is a fantastic opportunity for Orano Med to strengthen our commitment to developing innovative cancer treatments, engage with key industry stakeholders, and advance existing collaborations while exploring new partnership opportunities. 🤝 Expanding Our Collaboration with Molecular Partners Yesterday, we announced an expanded partnership with Molecular Partners, adding the development of six new targeted alpha therapeutic candidates to our pipeline - bringing the total to ten programs between the two companies. Arnaud Lesegretain, CEO of Orano Med: “The expansion of our collaboration with Molecular Partners underscores the strength and efficiency of our combined approach. Together, we have established a platform capable of significantly reducing development timelines for lead-212-based Radio-DARPin drug candidates. This partnership exemplifies how strategic synergies can drive innovation and accelerate the delivery of next-generation targeted alpha therapies to patients, and further diversifies vectorization technology in Orano Med’s pipeline.” Read the Press Release: https://lnkd.in/dXgGJ3Tp Arnaud Lesegretain Julien Torgue Thomas Daniel-Robin   #JPM2025 #OranoMed #MolecularPartners #HealthcareInnovation #NuclearMedicine #CancerResearch #RLT #Radiopharmaceuticals #Alphatherapy

Happy New Year! 🎉 2024 was a year of both challenges and achievements for Orano Med. Thanks to the dedication of our teams 💪 and strong collaboration with our partners 🤝, we made significant strides in the fight against cancer.   Among the key moments of 2024, we celebrated several decisive milestones: the groundbreaking for the ATLab in Valenciennes, followed by the inauguration of the ATLab in Indianapolis. We also received the FDA's Breakthrough Therapy Designation (BTD) for AlphaMedix, signed a licensing agreement with Sanofi for AlphaMedix, and Sanofi acquired a stake in Orano Med. To top it off, we ended the year with the groundbreaking for ATEF in Bessines-sur-Gartempe, a major facility in our industrial platform that will enable Orano Med to produce thorium-228, a precursor of lead-212, on a large scale for radioligand therapies. Check out our ATEF facility project in the video below 👇   To all our teams and partners: thank you for your dedication and trust throughout 2024 🙏. We have reached major milestones, advancing innovative solutions and bringing hope to patients worldwide 🌍. Let’s keep moving forward together in 2025 to make targeted alpha therapy for cancer patients a reality.   #OranoMed #HealthcareInnovation #NuclearMedicine #CancerResearch #RLT #Radiopharmaceuticals #Alphatherapy #TAT #France2030

Very honored and grateful for the opportunity to discuss the promise of Orano Med's 212-Pb based Targeted Alpha Therapies with Prof. Oliver Sartor and Uro Today:

We were thrilled to join the neuroendocrine tumor research community at #NANETS2024!   Our Phase 2 study results on ²¹²Pb-DOTAMTATE (AlphaMedix™) were presented by Prof. Jonathan Strosberg from Moffitt Cancer Center (Tampa, FL) at the North American Neuroendocrine Tumor Society Medical Symposium in Chicago.   The study focuses on targeted alpha therapy with ²¹²Pb-DOTAMTATE in subjects with advanced somatostatin receptor-expressing gastroenteropancreatic neuroendocrine tumors 🎯   These results showcase our commitment to driving innovation in oncology, with our most advanced treatment specifically targeting neuroendocrine tumors and offering new hope for patients.   Check out more details in the NANETS’24 Abstract Booklet (C-16) 👉 https://lnkd.in/dyg-GJte   #OranoMed #NANETS2024 #GEPNETS #Oncology #AlphaTherapy #MedicalInnovation #CancerResearch #Radiopharmaceuticals #RLT #FutureOfMedicine

🎉 Orano Med récompensée pour son engagement dans la réindustrialisation 🎉 Nous sommes fiers d’annoncer qu’Orano Med a reçu le prix « Réindustrialisation – Relocalisation » lors des Trophées Territoires et Industrie à Valenciennes ! 🏆 Organisé par La Gazette des communes et L'Usine Nouvelle, cet événement met en lumière les initiatives locales qui contribuent au développement industriel. À cette occasion, Laurent DROUGARD, directeur territoire chez Equans France, a remis à Orano Med le prix « Réindustrialisation – Relocalisation », saluant l’installation de notre usine de production de médicaments innovants, l’ATLab, dans la métropole de Valenciennes (Valenciennes Métropole). 🚀 Un projet ambitieux et porteur de retombées locales : 🔹 Production des premières doses prévue dès 2025. 🔹 Création de près d’une vingtaine de postes dès le démarrage de l’installation, avec des perspectives de recrutements supplémentaires selon notre développement. 🔹 Un impact local conséquent, avec 2 à 3 emplois indirects générés par salarié. Un grand merci à tous les partenaires et acteurs du territoire pour leur soutien. Ensemble, nous faisons de l’alphathérapie ciblée contre le cancer une réalité. 💪 #OranoMed #Réindustrialisation #Relocalisation #Innovation #Santé #Industrie #RLT #AlphathérapieCiblée #Valenciennes #France2030

🚀 Aujourd’hui marque une nouvelle avancée pour Orano Med dans la lutte contre le #cancer : la première pierre de notre nouvelle usine ATEF a été posée à Bessines-sur-Gartempe ! Cette installation sera la première au monde à produire à échelle industrielle du thorium-228, précurseur du plomb-212, pour des applications en #radiothérapie ciblée. 🎯 L'objectif de cette usine ? Approvisionner l’ensemble des sites ATLab (Alpha Therapy Laboratory) qui produiront les médicaments au plomb-212 destinés aux patients à travers le monde. D’ici à sa mise en service en 2027, l'usine ATEF permettra la création de près de 70 emplois directs et 100 emplois indirects et multipliera par 10 notre capacité de production. Un pas de plus vers des traitements innovants dans la lutte contre le cancer ! #OranoMed #Innovation #Santé #Cancer #Alphatherapie

🚀 It is with great enthusiasm that #OranoMed, today marks the groundbreaking of the ATEF facility in #BessinesSurGartempe! 🎉   ATEF will be our first industrial-scale facility dedicated to producing thorium-228, a key precursor of lead-212, for the manufacturing of radioligand therapies. This groundbreaking is the culmination of years of research and innovation and represents a significant step forward in our mission to provide transformative treatments for cancer patients worldwide.    🎯 This step is crucial in bringing targeted alpha therapy with lead-212 to patients with unmet medical needs, turning our vision into reality.   Our progress has been accelerated thanks to the support of the #France2030 plan and the #NextGenerationEU initiative, both of which are integral to advancing innovation in health and industry.   Thank you to all the Orano Med teams for their unwavering commitment and passion 🔥, which continue to carry our vision toward new horizons. Together, we are shaping a brighter future for patients 🌍   Learn more ➡️ https://lnkd.in/epKW-VZd   ---   🚀 C’est avec un grand enthousiasme que nous avons posé aujourd’hui la première pierre de notre usine ATEF à #BessinesSurGartempe ! 🎉   ATEF sera notre première usine à l’échelle industrielle dédiée à la production de thorium-228, un précurseur clé du plomb-212, pour la fabrication de radiothérapies internes vectorisées. Cette étape marque l’aboutissement d‘années de recherche et représente une avancée majeure dans notre ambition d’apporter des traitements innovants aux patients atteints de cancer dans le monde entier.   🎯 Cette étape est cruciale pour rendre les alphathérapies ciblées au plomb-212 accessibles aux patients dont les besoins médicaux ne sont pas satisfaits, et ainsi concrétiser notre ambition.   Ces progrès ont également été rendus possibles grâce au soutien du plan #France2030 et de l'initiative #NextGenerationEU, qui sont essentiels pour faire avancer l'innovation dans les domaines de la santé et de l'industrie.   Un grand merci à toutes les équipes d'Orano Med pour leur engagement sans faille 🔥 qui donne vie à notre vision et nous pousse à explorer de nouvelles perspectives. Ensemble, nous façonnons un avenir meilleur pour les patients 🌍   En savoir plus ➡️ https://lnkd.in/ezNkbUdN Claude Imauven Nicolas Maes Guillaume Dureau Julien Dodet Arnaud Lesegretain MBA, MMSc Bruno PAGNARD Sophie Letournel Marc Ferracci Isabelle Briquet Françoise Slinger-Cecotti Andréa Brouille Anne Jouvenceau-Bester Audrey Duval Frédéric Girard #OranoMed #Orano #RLT #MedicalInnovation #NuclearMedicine #France2030 #NextGenerationEU